Showing results (11-20 of 112) with videos related to

Sort By:
Pageof 12
Journal of Virology|November 23, 2007
Engineered disulfide bonds in herpes simplex virus type 1 gD separate receptor binding from fusion initiation and viral entryEric Lazear, Andrea Carfi, J Charles Whitbeck, et al.
Antibodies (Basel, Switzerland)|November 22, 2022
Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1Elisabeth Narayanan, Samantha Falcone, Sayda M Elbashir, et al.
Vaccine|September 9, 2015
Conformationally selective biophysical assay for influenza vaccine potency determinationYingxia Wen, Liqun Han, Giuseppe Palladino, et al.
Vaccines|May 18, 2016
Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African RegionsZihao Wang, Clarisse Lorin, Marguerite Koutsoukos, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2004
Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirusPaolo Ingallinella, Elisabetta Bianchi, Marco Finotto, et al.
Research Square|April 8, 2024
Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn virusesAlexander Bukreyev, Michelle Meyer, Bronwyn Gunn, et al.
Frontiers in Public Health|August 23, 2024
Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19Shehzad M Iqbal, Andrew M Rosen, Darin Edwards, et al.
Journal of Virology|December 23, 2004
Potential nectin-1 binding site on herpes simplex virus glycoprotein dSarah A Connolly, Daniel J Landsburg, Andrea Carfi, et al.
Vaccine|August 16, 2021
Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical modelsHelen Webster, Sarah Valencia, Amit Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 19, 2011
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titersKurt A Swanson, Ethan C Settembre, Christine A Shaw, et al.
Pageof 12